Business Wire

Laserfiche Joins the Boomi Technology Partner Program, Supporting the Automated, Connected Enterprise

Share

Laserfiche — the leading SaaS provider of intelligent content management and business process automation — today announced a partnership with Boomi, a leading provider of integration platform as a service known for its speed, ease-of-use, and low total cost of ownership. Through this partnership, organizations can simplify integrations between Laserfiche's robust content services platform and on-premises and cloud applications such as Salesforce, Workday, and Smartsheet using Boomi’s connectors to over 1,500 applications.

“Today’s connected enterprise is built on a robust technology infrastructure, which requires a centralized system to collect and monitor process data, paired with a simplified integration strategy,” said David Everson, Laserfiche’s senior director of strategic solutions. “Laserfiche is excited to bring a proven system for data centralization and process automation to the Boomi ecosystem, enabling more speed, greater agility and stronger security in our customers’ integrations.”

Laserfiche supports organizations in building end-to-end automated solutions that boost productivity, scale with growth and deliver digital-first customer experiences. Laserfiche customers can now take advantage of the enterprise content management (ECM) platform’s Boomi-powered connectors to mission-critical line-of-business applications accelerate integration deployment, more easily manage integration lifecycles and access organization-wide data analytics. The Laserfiche and Boomi partnership is enabling customers to configure and expedite solutions such as:

  • Streamlined recruiting and new employee onboarding to move candidates through the hiring process quickly
  • Sending/retrieving data to/from popular storage and databases for more flexible data queries and reporting
  • Streamlined invoice processing to gain real-time visibility into accounts payable
  • Syncing client updates to provide the business with a more holistic view of the client
  • Simplified authentication for secure connections to applications

According to The Forrester Wave™: Enterprise iPaaS, Q4 2021, “As more organizations embrace cloud-native, applications and data are more distributed than ever before. Delivering those user experiences and digital business capabilities requires an integration platform that stitches together the ever-growing number of distributed apps and data. Furthermore, the pandemic and quarantines accelerated the need for business process automation and has squeezed IT beyond what it can deliver. In response, organizations are embracing citizen iPaaS as a tool in their business process automation strategy.”

The Boomi Technology Partner Program includes enterprise software companies across applications such as CRM, ERP, HRIS and business intelligence, as well as across industries including government, education, financial services, healthcare and manufacturing. Boomi provides organizations with greater scalability and greater control over data orchestration between application transactions, allowing connectivity to scale as organizations adopt a wider range of solutions.

“We are excited to have Laserfiche as part of our Technology Partnership Program,” said Reggie Penn, global head of technology alliances at Boomi. “A leader in the enterprise content management space, Laserfiche is a solid addition to our profile of partners that offer real solutions that help organizations solve their biggest challenges. The collaboration between Laserfiche and Boomi positions our mutual customers to meet the growing demand for integrations and keep up with the rapid pace of innovation.”

Learn more about the Laserfiche and Boomi partnership by visiting the Laserfiche website.

About Laserfiche

Laserfiche is the leading SaaS provider of intelligent content management and business process automation. Through powerful workflows, electronic forms, document management and analytics, the Laserfiche® platform accelerates how business gets done, enabling leaders to focus on growth across the enterprise.

Laserfiche pioneered the paperless office with enterprise content management. Today, Laserfiche’s cloud-first development approach incorporates innovations in machine learning and AI to enable organizations in more than 80 countries to transform into digital businesses. Customers in every industry — including government, education, financial services, healthcare and manufacturing — use Laserfiche to boost productivity, scale their business and deliver digital-first customer experiences.

Laserfiche employees in offices around the world are committed to the company’s vision of empowering customers and inspiring people to reimagine how technology can transform lives.

Connect with Laserfiche:

Laserfiche Blog | Twitter | LinkedIn | Facebook

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Linda Domingo
Director, Public Relations, Laserfiche
Linda.domingo@laserfiche.com
562-988-1688 ext. 234

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye